Straathof, K. C., A. M. Leen, E. L. Buza, G. Taylor, M. H. Huls, H. E. Heslop, C. M. Rooney, and C. M. Bollard. 2005. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J. Immunol. 175: 4137–4147 .

In Table I, the HLA restrictions for two of the LMP2 epitopes are incorrect. The correct HLA restriction for TVCGGIMFL in the sixth row should be A*0201/06 and for LLWTLVVL in the seventh row should be A*0201. The corrected table is shown below.

Table I.

LMP2-specific T cell populations in patient CTL linesa

Minimum EpitopeAmino AcidsHLA RestrictionNo. Responding/No. TestedSFC/105 CTL (range)
CLGGLLTMV 416–434 A*0201/06/07/09 4/12 84 (19–236) 
GLGTLGAAI 293–301 A2 1/12 459 
LTAGFLIFL 453–461 A2 0/12  
FLYALALLL 356–364 A*0201 7/12 381 (7–1990) 
LIVDAVLQL 257–265 A*0204 or A*0217 1/12 651 
TVCGGIMFL 243–251 A*0201/06 2/12 198 (175–222) 
LLWTLVVL 329–337 A*0201 2/12 19 (14–24) 
FTASVSTVV 144–152 A68 2/6 38 (23–53) 
SSCSSCPLSKI 340–350 A11 3/3 43 (8–90) 
TYGPVFMSL 419–427 A24 2/5 58 (16–101) 
PYLFWLAAI 131–139 A23/24 3/6 462 (12–1132) 
ILLARLFLY 349–358 A29 1/2 
RRWRRLTVC 237–245 B*1402 1/1 41 
RRRWRRLTV 236–244 B*2704/05/09 1/2 16 
RRLTVCGGIMF 240–250 B27 1/3 129 
MGSLEMVPM 1–9 B*3501 1/5 880 
LPVIVAPYL 125–133 B53 1/2 
IEDPPFNSL 200–208 B60 1/2 918 
DYQPLGTQDQSLYLG 73–87 DR4 or DR16 1/1 57 
Minimum EpitopeAmino AcidsHLA RestrictionNo. Responding/No. TestedSFC/105 CTL (range)
CLGGLLTMV 416–434 A*0201/06/07/09 4/12 84 (19–236) 
GLGTLGAAI 293–301 A2 1/12 459 
LTAGFLIFL 453–461 A2 0/12  
FLYALALLL 356–364 A*0201 7/12 381 (7–1990) 
LIVDAVLQL 257–265 A*0204 or A*0217 1/12 651 
TVCGGIMFL 243–251 A*0201/06 2/12 198 (175–222) 
LLWTLVVL 329–337 A*0201 2/12 19 (14–24) 
FTASVSTVV 144–152 A68 2/6 38 (23–53) 
SSCSSCPLSKI 340–350 A11 3/3 43 (8–90) 
TYGPVFMSL 419–427 A24 2/5 58 (16–101) 
PYLFWLAAI 131–139 A23/24 3/6 462 (12–1132) 
ILLARLFLY 349–358 A29 1/2 
RRWRRLTVC 237–245 B*1402 1/1 41 
RRRWRRLTV 236–244 B*2704/05/09 1/2 16 
RRLTVCGGIMF 240–250 B27 1/3 129 
MGSLEMVPM 1–9 B*3501 1/5 880 
LPVIVAPYL 125–133 B53 1/2 
IEDPPFNSL 200–208 B60 1/2 918 
DYQPLGTQDQSLYLG 73–87 DR4 or DR16 1/1 57 
a

Listed are the amino acid sequence of newly identified (in bold) as well as previously described LMP2 epitopes (27–33); their location in the LMP2 molecule; HLA restriction; the number of CTL lines from NPC, HL, and NHL patients in which responses to these epitopes were identified; and the strength of these responses. When responses to the indicated epitope were found in more than one patient, CTL line average response and range are shown.